Introduction
Leukemia is a hematological neoplasm that is characterized by the uncontrolled proliferation of immature leukocytes (1-3).
Currently, the incidence of leukemia is increasing worldwide (4) . In 2012, a total of 47,150 new cases were diagnosed in the United States (5, 6) . Although leukemia has been considered to be a treatable disease, the rates of successful treatment and long-term survival rate remain low, particularly for patients with certain types of leukemia, such as those with complex karyotypes (7) . Previous studies have demonstrated that genetic mutations and environmental factors are associated with the development of leukemia (8) (9) (10) . However, the pathogenesis of leukemia and factors that regulate leukemic cell proliferation are not fully understood.
Previous studies have indicated that bone marrow angiogenesis is crucial for the pathogenesis of human leukemia (11) . Vascular endothelial growth factor (VEGF) is a growth factor that stimulates vasculogenesis and angiogenesis (12) . The VEGF receptors (VEGFRs) are members of the tyrosine kinase c-fms family of proteins (13) . There are three VEGFRs, the fms-like tyrosine kinase-1 (Flt-1), also termed VEGFR-1, and the kinase insert domain-containing receptors (KDRs), also termed VEGFR-2 and VEGFR-3 (14) . VEGF plays key roles in angiogenesis, physiological embryogenesis, pathological tumorigenesis and metastasis (15) (16) (17) (18) . While treatment with bevacizumab to neutralize VEGF has been revealed to inhibit the growth of solid tumors in human patients and rodent models of cancer, VEGF is also a crucial factor for the proliferation of immature leukocytes and leukemic cells in the bone marrow (19) . Increased levels of serum VEGF and bone marrow microvessel density (BM-MVD) are observed in patients with various types of hematological malignancies and are associated with the severity of disease in patients with leukemia (20) (21) (22) (23) . Decreased levels of BM-MVD and serum VEGF are detected in patients with acute myeloid leukemia (AML) subsequent to remission (24) . Furthermore, increased levels of BM-MVD are associated with a poor prognosis in patients with AML (21) . However, there is little information on the presence of altered levels of BM-MVD and serum VEGF in Chinese patients with hematological neoplasms.
In the present study, the levels of BM-MVD, BM VEGF and serum VEGF were examined in 62 Chinese patients with various hematological disorders, prior to and following the administration of standard chemotherapies, and the implications of the present findings are discussed. Sample collection. Fasting venous blood samples and samples obtained from bone marrow aspiration and biopsy were collected from individual patients, as previously described (20) (21) (22) (23) (24) . The individual blood and bone marrow aspiration samples were subjected to centrifugation at 1,000 x g for 10 min, and the resulting plasma samples and bone marrow supernatants were stored at -80˚C.
Levels
Treatment. Patients with acute promyelocytic leukemia (M3 AML) were treated with a daily dose of 8-10 mg arsenic trioxide for 28 days, and patients with other types of AML (M0, M1, M2, M4, M5, M6 and M7) were treated with the HA protocol, consisting of a homoharringtonine base with cytarabine, DA protocol, consisting of daunorubicin and cytarabine, or IDA protocol, consisting of idarubicin and cytarabine. Patients with NHL were treated using the CHOP protocol, consisting of cyclophosphamide, doxorubicin, vincristine and prednisone, or the R-CHOP protocol, consisting of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. Patients with anemia were treated with a supplement of hematogenic materials. A total of 16 patients with AML underwent blood and bone marrow sampling again at 28-30 days subsequent to the previous treatment. The therapeutic efficacy of individual patients was evaluated, according to the previously reported criteria (28) .
Immunohistochemistry. The BM-MVD of individual biopsy samples was determined by immunohistochemistry, as previously described (26, 28) . Briefly, the bone marrow biopsy samples were fixed in cold acetone for 2 h and embedded in alcohol-ethylene methacrylate (The Sixth People's Hospital of Shanghai, Shanghai, China). The bone marrow tissue samples were sliced into 4-µM thick sections, and were treated with 0.4% pepsin and then 3% methanol, followed by blocking with 10% goat sera. Subsequently, the tissue sections were stained with polyclonal rabbit anti-human von Willebrand factor antibodies (vWF; dilution, 1:500; RAB-0068; Maixin Biotechnology, Fuzhou, Fujian, China) overnight at 4˚C, as vWF is expressed by megakaryocytes and endothelial cells and easily identified microvascular endothelial cells (26) . By contrast, other biomarkers, such as cluster of differentiation (CD)31, CD34 or Ulex europaeus agglutinin 1, are not easily used for the measurement of BM-VMD. Subsequent to being washed, the bound antibodies were detected using horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG and visualized using diaminobenzidine (DAB). The control sections were treated with rabbit sera from healthy animals. The numbers of microvessels were determined in a blinded manner, as previously described (24, 29, 30) . First, three hot-spot areas of anti-vWF staining were identified (magnification, x100) and images were captured (magnification, x400). Individual vessels with brown-yellow stained endothelial cells were counted three times if they separated clearly from adjacent blood vessels and trabecular bone, regardless of whether there was a vascular lumen and whether the vascular lumen contained red blood cells. At least 10 staining areas of three sections from individual samples were evaluated and the value of BM-MVD was calculated for each sample.
ELISA. The concentrations of plasma and bone marrow supernatant VEGF were determined by ELISA using the VEGF ELISA kit (JingMei Biotech, Co., Ltd., Beijing, China), as previously described (26, 28, 31) . Briefly, plasma samples were diluted with sample diluents at a ratio of 1:3, while the bone marrow supernatants were diluted at a ratio of 1:5 for analysis. The samples from the various groups of patients and HC individuals were simultaneously analyzed, and individual samples were tested in triplicate and repeated three times. The concentrations of VEGF in individual samples were calculated, according to the standard curve established using recombinant human VEGF provided.
Data analysis. Data are expressed as the mean ± standard deviation or the median and range if applicable. The difference between groups was analyzed by Student's t-test, χ 2 -test, the Mann-Whitney U test or Wilcoxon rank-sum test using SPSS 13.0 software (SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.
Results

Significantly increased levels of serum and BM VEGF and BM-MVD in patients with AML. VEGF is crucial for angiogenesis and supports the growth of solid tumors (32,33).
The BM-MVD is important for the pathogenesis of human leukemia (34) . To examine the importance of VEGF and BM-MVD, a group of patients with different hematological disorders and 10 gender and age-matched HC individuals were recruited. The demographic and clinical characteristics are summarized in Table I . There is no significant difference in the distribution of age and gender. Analysis of VEGF indicated that the levels of serum VEGF in patients with AML (74.97±29.04), NHL (146.89±74.67) or benign anemia (122.05±45.23) were significantly increased compared with the levels in the HC individuals (41.76±10.03) (P<0.01; Table II ). The levels of BM VEGF in patients with AML (150.58±73.36) were significantly higher compared with the levels in the patients with NHL (100.39±28.10) or benign anemia (94.85±30.55) (P<0.05). Furthermore, the levels of BM-MVD in patients with AML (22.28±6.89) were also significantly increased compared with the levels in patients with NHL (7.76±2.24) or benign anemia (11.11±2.35) (P<0.01). Therefore, significantly increased levels of serum and BM VEGF and BM-MVD were detected in patients with AML.
Chemotherapy alters levels of serum, BM VEGF and BM-MVD in patients with AML.
Following chemotherapy, 16 out of 28 patients were followed up and 9 patients (AML-CR) were completely recovered, while 7 patients (AML-NR) had not demonstrated recovery at 6 months subsequent to the last chemotherapy. The levels of serum VEGF in both AML-CR (146.02±40.48) and AML-NR (151.03±20.73) groups of patients were significantly increased compared with the levels prior to treatment (74.97±29.04) (P<0.01; Table III) , and there was no significant difference in the levels of The MVD value is presented as the number of microvessels per high-power field (magnification, x400). VEGF, vascular endothelial growth factor; B-VEGF, blood plasma VEGF; BM-VEGF, bone marrow VEGF; MVD, microvessel density; AML, acute myeloid leukemia; HC, healthy controls; NHL, non-Hodgkin's lymphoma. The MVD value is presented as the number of microvessels per high-power field (magnification, x400). VEGF, vascular endothelial growth factor; B-VEGF, blood plasma VEGF; BM-VEGF, bone marrow VEGF; MVD, microvessel density; AML, acute myeloid leukemia; AML-NR, no recovery from AML at 6 months post-chemotherapy; AML-CR, complete remission of AML; AML-DFS, complete recovery from AML demonstrated for 6 months post-chemotherapy.
serum VEGF between the AML-CR and AML-NR groups of patients. By contrast, the levels of BM VEGF in the AML-CR (109.19±49.82) and AML-NR (109.82±14.50) groups of patients were significantly lower compared with the levels prior to treatment (150.58±73.36) (P<0.05). Similarly, the levels of BM-MVD in the AML-CR patients were significantly lower compared with the levels present prior to treatment (8.89±2.60 vs. 22.28±6.89; P<0.01). However, the levels of BM-MVD in the AML-NR patients were slightly reduced compared with the levels prior to treatment, but this difference was not significant (18.08±1.21 vs. 22.28±6.89; P>0.05). Notably, the levels of BM-MVD in the AML-CR group were also significantly decreased compared with the levels in the AML-NR group (P<0.05). This finding indicates that a dramatic decrease in the levels of BM-MVD is associated with complete remission in patients with AML. In addition, the levels of serum VEGF, BM VEGF and BM-MVD in 14 AML-DFS patients were also assessed. Similar levels of serum VEGF were detected in the AML and AML-DFS patients, but significantly lower levels of BM VEGF in the AML-DFS patients compared with the AML group (61.67±3.15 vs. 150.58±73.36; P<0.01). Notably, the levels of BM-MVD in the AML-DFS group were similar to the levels in the AML-CR patients, but were significantly lower compared with the levels in the AML (6.48±2.09 vs. 22.28±6.89; P<0.01) and AML-NR patients (6.48±2.09 vs. 18.08±1.21; P<0.05). The present data indicate that the levels of BM-MVD vary in different stages of AML and may be inversely associated with the activity of the disease.
Discussion
VEGF is crucial for vasculogenesis and angiogenesis, and plays key roles in the development and progression of leukemia (1) (2) (3) . Although angiogenesis in acute leukemia has already been extensively studied, it is unknown whether there is any difference between the Chinese population and other populations (35) . In the present study, the levels of serum and BM VEGF, and BM-MVD were measured in newly diagnosed patients with AML, NHL and benign anemia. It was found that the levels of serum VEGF in patients with AML, NHL and anemia were significantly increased compared with the levels in the HC individuals and that the levels of serum VEGF in patients with AML were significantly decreased compared with the levels in patients with NHL or benign anemia. Furthermore, the levels of BM VEGF and BM-MVD in AML patients were significantly increased compared to patients with NHL or anemia. The present data were consistent with previous observations in other populations (36) (37) (38) and suggest that hematological disorders may promote the production of VEGF, particularly in patients with AML. The significantly increased levels of BM VEGF and BM-MVD in AML patients suggests that VEGF-associated vasculogenesis and angiogenesis may support the proliferation of malignant progenitor cells and may be associated with the pathogenesis of AML. In addition, VEGF may be a target for the design of novel therapies for AML.
Previous studies have revealed that antitumor chemotherapeutics inhibit angiogenesis and induce apoptosis of endothelial cells (26, 39) . In the present study, it was found that subsequent to the administration of chemotherapy, significantly increased levels of serum VEGF and reduced levels of BM VEGF were detected in the patients with AML, regardless of whether they markedly responded to the therapies. Furthermore, the levels of BM-MVD in the drug-responders that completely recovered from AML were significantly reduced, compared with the levels prior to treatment. In AML-DFS patients, the levels of BM VEGF and BM-MVD were lowest compared with the levels in patients with AML prior to treatment, and in AML-NR and AML-CR patients. These data suggest that the reduced levels of BM VEGF may mitigate AML-associated vasculogenesis and angiogenesis and decrease the levels of BM-MVD in the drug-responders of AML patients. The outcome may stem from chemotherapeutic drugs that inhibit the proliferation of endothelial cells and induce endothelial cell apoptosis (26, 39) . Provided that vasculogenesis and angiogenesis are crucial for the proliferation of malignant progenitor cells, the reduced levels of BM-MVD may contribute to complete recovery in these AML patients (40) . Therefore, the measurement of BM-MVD may serve as a biomarker for evaluating the status of AML and prognosis of chemotherapeutic responses.
In summary, the present data indicated significantly increased levels of serum VEGF in patients with AML, NHL or benign anemia and that the levels of BM VEGF and BM-MVD in AML patients were significantly increased compared with patients with NHL or anemia. Treatment with chemotherapeutic agents dramatically reduced the levels of BM VEGF and BM-MVD in the AML patients, and the change in the levels of BM-MVD was associated with the drug response in AML patients. Therefore, the levels of BM-MVD may serve as a biomarker for evaluating the status of AML and the therapeutic responses in AML patients.
